These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 16922468)
1. Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET. Fujimoto R; Higashi T; Nakamoto Y; Hara T; Lyshchik A; Ishizu K; Kawashima H; Kawase S; Fujita T; Saga T; Togashi K Ann Nucl Med; 2006 Jul; 20(6):399-408. PubMed ID: 16922468 [TBL] [Abstract][Full Text] [Related]
2. A comparative study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and (99m)Tc-MDP whole-body bone scanning for imaging osteolytic bone metastases. Zhang L; Chen L; Xie Q; Zhang Y; Cheng L; Li H; Wang J BMC Med Imaging; 2015 Mar; 15():7. PubMed ID: 25885599 [TBL] [Abstract][Full Text] [Related]
3. 18F-fluorodeoxyglucose-positron emission tomography and bone scintigraphy for detecting bone metastases in patients with malignancies of the upper aerodigestive tract. Kim MR; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY Oral Oncol; 2008 Feb; 44(2):148-52. PubMed ID: 17350879 [TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Qiu ZL; Xue YL; Song HJ; Luo QY Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353 [TBL] [Abstract][Full Text] [Related]
6. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Abe K; Sasaki M; Kuwabara Y; Koga H; Baba S; Hayashi K; Takahashi N; Honda H Ann Nucl Med; 2005 Oct; 19(7):573-9. PubMed ID: 16363622 [TBL] [Abstract][Full Text] [Related]
8. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma? Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285 [TBL] [Abstract][Full Text] [Related]
9. The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer. Min JW; Um SW; Yim JJ; Yoo CG; Han SK; Shim YS; Kim YW J Korean Med Sci; 2009 Apr; 24(2):275-80. PubMed ID: 19399270 [TBL] [Abstract][Full Text] [Related]
10. Comparison of (18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma. Byun BH; Kong CB; Lim I; Kim BI; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM Skeletal Radiol; 2013 Dec; 42(12):1673-81. PubMed ID: 23995264 [TBL] [Abstract][Full Text] [Related]
11. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan? Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321 [TBL] [Abstract][Full Text] [Related]
12. Comparison between whole-body positron emission tomography and bone scintigraphy in evaluating bony metastases of esophageal carcinomas. Kato H; Miyazaki T; Nakajima M; Takita J; Kimura H; Faried A; Sohda M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K Anticancer Res; 2005; 25(6C):4439-44. PubMed ID: 16334123 [TBL] [Abstract][Full Text] [Related]
13. Significance of hormone receptor status in comparison of 18F -FDG-PET/CT and 99mTc-MDP bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience. Teke F; Teke M; Inal A; Kaplan MA; Kucukoner M; Aksu R; Urakci Z; Tasdemir B; Isikdogan A Asian Pac J Cancer Prev; 2015; 16(1):387-91. PubMed ID: 25640386 [TBL] [Abstract][Full Text] [Related]
14. Is (99m)Tc-MDP whole body bone scintigraphy adjuvant to (18)F-FDG-PET for the detection of skeletal metastases? Sahin E; Zincirkeser S; Akcan AB; Elboga U J BUON; 2014; 19(1):291-6. PubMed ID: 24659678 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases. Chang CY; Gill CM; Joseph Simeone F; Taneja AK; Huang AJ; Torriani M; Bredella MA Acta Radiol; 2016 Jan; 57(1):58-65. PubMed ID: 25533313 [TBL] [Abstract][Full Text] [Related]
16. Comparison of (18)F-FDG-PET/CT with (99m)Tc-MDP bone scintigraphy for the detection of bone metastases in cancer patients. Ozülker T; Küçüköz Uzun A; Ozülker F; Ozpaçac T Nucl Med Commun; 2010 Jun; 31(6):597-603. PubMed ID: 20224457 [TBL] [Abstract][Full Text] [Related]
17. Comparison of 18F-FDG PET/CT scan and 99mTc-MDP bone scintigraphy in detecting bone metastasis in head and neck tumors. Al-Bulushi NK; Abouzied ME Nucl Med Commun; 2016 Jun; 37(6):583-8. PubMed ID: 26813992 [TBL] [Abstract][Full Text] [Related]
18. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635 [TBL] [Abstract][Full Text] [Related]
19. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. Ito S; Kato K; Ikeda M; Iwano S; Makino N; Tadokoro M; Abe S; Nakano S; Nishino M; Ishigaki T; Naganawa S J Nucl Med; 2007 Jun; 48(6):889-95. PubMed ID: 17504877 [TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]